Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is focused on improving the early detection and management of cancer and other chronic diseases through diagnostics telehealth programs. Its lead product, Aristotle, is a mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high... see more

TSX:SZLS - Post Discussion

StageZero Life Sciences Ltd > Warrant reprice in effect for the next 3 trading days
View:
Post by LithLover on Jul 05, 2023 4:59pm

Warrant reprice in effect for the next 3 trading days

8,730,647 outstanding common share purchase warrants. The new exercise price of the warrants will be CDN$0.065 and the temporary repricing will take effect on July 5 and close on July 10, 2023. We believe this represents a great opportunity to those shareholders who have supported us over the last few years to participate further in the growth of StageZero and represents CDN $567,492 in possible capital to StageZero should all of the warrants be exercised. This capital would be directly deployed into growth focused activities such as the METRICS II study and support of our growing list of partnerships.
-------------

Hard to buy any significant shares in the market at 0.065 or higher as it would drive the price up and only 100,000 or so was available.  We will see what happens and if there is any interest in the 8.7 million warrants.  

Current level 2 ask:


0.070 132,000
 
132,000 shares
0.075 25,000
 
25,000 shares
0.080 82,000
 
82,000 shares
0.085 73,000
 
73,000 shares
0.090 12,000
Comment by telman on Jul 05, 2023 5:50pm
yeah i got the same copy and past reply from them. I bought the poor people warrants so i lost it all.   Nice little F you for holding them for so long and now I get the joy of having to call my bank to get the info removed from my account so i dont have to stare at it until I die. I see the SP went up today on another massive day of trading. We all know if the SP goes up a little ...more  
Comment by LithLover on Jul 05, 2023 6:16pm
The financing is a discount to the average share trading price and includes warrants.  So GEM would be at 0.05-0.055 and they get warrants too.  These repriced are at 0.065 and no extra warrants.  Ends up being 20% better and no extra warrants to issue.  Plus those financiers with higher exercise price could actually make some money rather than lose when warrants expire.  
Comment by Liked2Think on Jul 05, 2023 6:55pm
Oh please yes make sure those financiers with big bucks make money.  The average joe that bought above a dollar while pumpers and management pumped and lied can go F themselves.  the normal shares will be at $0.005 in only a matter of time.  the fact that management and Rebecca give investors that message them nothing but bs like them questioning that loser "why didn' ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities